Nanoparticles derived from insect exoskeleton modulates NLRP3 inflammasome complex activation in cervical cancer cell line model

Ritupama Chakraborty
Melaka Manipal Medical College

Ujjal Bose
Melaka Manipal Medical College

Goutam Mohan Pawaskar
Manipal Institute of Technology

Satish BS Rao
Manipal Academy of Higher Education

Ritu raval (ritu.raval@manipal.edu)
Manipal Institute of Technology  https://orcid.org/0000-0003-1297-3291

Research

Keywords: Chitosan nanoparticles, Gallic acid, NLRP3 inflammasome, HeLa 229cell line

DOI: https://doi.org/10.21203/rs.3.rs-385612/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Immune evasion is an important hallmark of cancer progression and tumourigenesis. Among the cancer types, cervical cancer has very high global prevalence, severely affecting female reproductive health. Its preponderance is also observed in the Indian health sector.

Results: The NLRP3 inflammasome, an intracellular complex regulates the innate immune activity and a variant gene of it has been significantly associated with cervical cancer development. We aimed to evaluate the potential role of our chitosan engineered nanoparticles (CSNP) and gallic acid conjugated chitosan (gCSNP), to modulate the NLRP3 inflammasome complex in cervical cancer cell lines to explore their novel physicochemical properties. The encapsulation of gallic acid (GA) with chitosan was performed using ion gelation method. The CSNP and gCSNP nanoparticles ranged between 155 - 181 nm as determined by zeta sizer. The conjugations were validated by FTIR and XRD analysis. In the cervical cell line model, CSNP suppressed NLRP3 inflammasome activation in contrast to gCSNP at higher doses.

Conclusion: In contrast to gCSNP, the CSNP not only demonstrated inhibitory effect on the expression of genes coding for the NLRP3 inflammasome complex (signal 1 – priming) but also decreased relative expression of gene involved in the activation of NLRP3 inflammasome complex (signal 2 – activation). Conjugation of gallic acid reversed the immunosuppressor mimicking action of CSNP in cervical cancer cell line. Future research can reveal the immunomodulatory mechanism of CSNP may have its translational significance as potential treatment strategies targeting immune evasion as an important hallmark of cancer.

Background

Cervical malignancy is the fourth most prevalent neoplasm globally and second most common among Indian women (Arbyn et al. 2020; Mishra et al. 2016). Inflammation induced through microbial or danger signals affects all stages of tumour development. The pro-inflammatory cytokines, IL-1β and IL-6, are important mediators for inflammation-induced tumourigenesis (Moossavi et al. 2018). The NLRP3 inflammasome is a multimeric protein complex that regulates the innate immune activity through modulation of the production of pro-inflammatory cytokines. A variant NLRP3 gene has been significantly associated with cervical cancer development (Pontillo et al. 2016). However, the role of NLRP3 inflammasome activation in tumourigenesis, transformation and invasion, remains a conundrum (Moossavi et al. 2018). Activation of the NLRP3 inflammasome is a two-step process where microbial toxins or danger signals and ATP are necessary for inflammasome activation. There is a lack of adequate therapeutic strategies targeting key immune signalling pathways involving the inflammasome complex in cancer treatment.

Nanoparticles hold promise in offering a unique opportunity that increases the efficiency of cancer immunotherapy as well as ameliorates their toxic side-effects (Hamarsheh and Zeiser 2020; Park et al.
We hypothesize that our engineered nanoparticles - CSNP/gCSNP can prevent the outcome of the priming signal by inhibiting the expression of genes coding for the NLRP3 inflammasome complex proteins in human cervical epithelial adenocarcinoma cells. Furthermore, we aimed at studying the role of CSNP/gCSNP on the genes coding for the purinergic receptor (P2RX7) which functions as a major contributor in providing the second kick necessary for activating the NLRP3 inflammasome complex. Additionally, the study aimed at evaluating the effect of our engineered nanoparticles on the gene coding for pro-inflammatory cytokine IL1β and its release from stimulated cervical cancer cells.

A pilot study by one of our co-investigators indicated a positive effect of chitosan-based nanoparticles and oligosaccharides on the anti-inflammatory cytokines, in the in vivo study conducted on the cyclophosphamide treated mice model (Mudgal et al. 2019). As an extension of these findings, this study was undertaken to investigate the effect of chitosan nanoparticles on the NLRP3 inflammasome complex to establish the relationship between innate immunity, inflammation and disease progression in cervical cancer cell line model.

Cancer immunotherapy has come a long way to significantly augment conventional cancer therapy in recent years (Kruger et al. 2019; Sun 2017). Although, NLRP3 inflammasome has been implicated both in tumourigenesis and as a response to antitumour therapy, it provides a lucrative target for cancer immunotherapy (Hamarsheh and Zeiser 2020; Kantono and Guo 2017; Karki and Kanneganti 2019). Hence the present study further investigated the multipronged potential of CSNP/gCSNP as a robust immune modulator in cervical cancer cells, to address the molecular mechanisms behind the activation of inflammasomes. Here, we not only targeted the expression of critical genes in the canonical pathway but also the activation mechanism of the NLRP3 inflammasome complex in cervical cancer cells. Moreover, the present study aimed at exploring the possibilities of pharmacological potential of the CSNP nanoparticles and its modified form as gCSNP.

**Material And Methods**

**Preparation of chitosan and gallic acid conjugated chitosan nanoparticles**

The chitosan nanoparticles (CSNP) were prepared based on the modified ionotropic gelation method reported by Calvo and co-workers (Calvo et al. 1997). The gallic acid conjugated chitosan nanoparticles (gCSNP) were synthesized based on the report by Lamarra et al (2017) (Lamarra et al. 2017). The loading efficacy of gallic acid (GA) in the chitosan nanoparticles was estimated by the method of Ainsworth with some modifications (Ainsworth and Gillespie 2007).

**Physicochemical characterization of engineered nanoparticles**

The formulated nanoparticles (NP) were dissolved in an appropriate volume of HPLC grade water and the average hydrodynamic diameter, polydispersity index (PDI) and zeta potential were estimated with ZetaSizer Nano ZS90 (Malvern Instruments Limited, UK) equipped with a 4.0 mW He-Ne laser. The detection angles of 90° and 120° were used for determination of a) size and PDI and b) the
zeta potential of the synthesized nanoparticles respectively. The FTIR spectra of CSNP, gCSNP and GA were recorded on a Jasco FT/IR-6300 Spectrometer equipped with a DR PRO410-M (Jasco, Japan) by scanning from 4000 to 500 cm\(^{-1}\) at a resolution of 4 cm\(^{-1}\) and analysed using Microsoft Excel (Microsoft Office version 2016, USA). The crystallographic structures of CSNP and formulated gCSNP were acquired on a Rigaku Ultima MiniFlex 600 X-ray diffractometer (Rigaku, Germany) using 119 Cu Ka radiation operating at 40 kV and 15 mA.

**In vitro studies to evaluate the effect of engineered nanoparticles on NLRP3 inflammasome activated cervical adenocarcinoma cell line (HeLa 229) model**

HeLa 229 cell line was procured from the National Centre for Cell Science, Pune and the passage no. 102 was used in the present study. Cells were maintained in DMEM (Gibco, India) supplemented with 10% fetal bovine serum (Gibco, India) and 1% penicillin-streptomycin (Merck, India) at 37\(^\circ\)C in 5% CO\(_2\) humidified incubator (Thermo Fisher Scientific, India).

**Cytotoxicity assay**

MTT Cell Growth Assay (CT02, Merck, India) was used for assessing the 24 hour cytotoxicity of CSNP and gCSNP on HeLa 229 cell line. The cytotoxicity assay was used only as a reference for dose selection of the engineered nanoparticles since the selected doses were used for a time duration limited to 5 hours as per the present study design.

**Drug treatment**

HeLa 229 cells were stimulated with lipopolysaccharide (LPS) obtained from *Escherichia coli* 0111: B44 (Merck, India) at the start of experiment and ATP (Merck, India) was added after 3.5 hours of incubation at 37\(^\circ\)C in 5% CO\(_2\) humidified incubator. The test nanoparticles were administered in three doses (0.6\(\mu\)g/ml (CSNP1/gCSNP1), 6\(\mu\)g/ml (CSNP2/gCSNP2) and 12\(\mu\)g/ml (CSNP3/gCSNP3)) along with LPS and harvested after 4.5 hours from the start of the experiment.

**Relative mRNA expression of genes coding for activated NLRP3 inflammasome complex in cervical cancer cell line**

The total RNA was extracted from HeLa 229 cells homogenized in TRI-Reagent (T9424, Merck, India) following the manufacturer's protocol. The extracted RNA was carefully assessed for its quality, purity and integrity using the 260/280 ratio, 260/230 ratio obtained from BioSpectrometer basic, (6135000009, Eppendorf, India) and agarose gel electrophoresis (intact gel bands corresponding to 28S and 18S RNA) respectively. The extracted RNA from each group was diluted to 180 ng/\(\mu\)l using nuclease free water to ensure a known amount of starting mRNA concentration from every group for cDNA synthesis. High-Capacity Reverse Transcriptase cDNA synthesis kit (ThermoFisher Scientific India Pvt. Ltd., India) was used to prepare cDNA (final volume of 20 \(\mu\)l) from the extracted total RNA using thermocycler (Mastercycler X50, Eppendorf, India). Synthesis of cDNA involved the use of random
primers from the cDNA synthesis kit with internal controls as +RT/-RT (with or without Reverse Transcriptase) to reduce experimental errors. TaqMan™ 20X Assay probes (Table 1, ThermoFisher Scientific, India) were mixed with Universal PCR Master Mix (4304437, Applied Biosystems™, ThermoFisher Scientific, India) for the qPCR experiments. Quantitative polymerase chain reaction (qPCR) was performed in CFX96 (BioRad, India) to assess the relative change in mRNA expression of genes coding for activated NLRP3 inflammasome complex proteins. The PCR conditions used were as follows: To achieve a maximum of the reaction, conditions used were optimised for 20μl of the reaction volume with initial denaturation step (hold at 95°C for 10 minutes) followed by 40 cycles of 95°C for 15 seconds, 60°C (TaqMan 20X assay specific) for 1 minute followed by a final hold at 4°C.

On completion, the plates were stored at -20°C and the mean cycle quantification (Cq) values were recorded (Bustin et al. 2009). Fluorescence signals were detected in the channel 1: Fam (CFX96, Bio-Rad, India). The efficiency of the gene assay mixes was determined using standard dilution method following MIQE guidelines (Bustin et al. 2009). The recorded Cq values from the test group was normalized against efficiency of assay 20X for each gene, sample mRNA amount, number of experimental repeats, number of qPCR repeats and with Cq values of three selected reference genes that were most stably expressed across all experiments. Relative expression of genes for the test groups was compared with that of control and represented by converting to their .

**Estimation of secreted IL-1β**

Quantitative ELISA was performed with the Human IL-1β ELISA Kit (BMS224-2, Invitrogen, India) following manufacturer’s instructions using ELISA reader (iMark microplate reader, BioRad, India). This method was used to estimate the secreted IL-1β present in the supernatants of NLRP3 inflammasome stimulated HeLa 229 cells for every test groups and control.

**Statistical analysis**

All experiments were performed in triplicates and statistical significance of variation was determined using One-way ANOVA with appropriate Posthoc test using GraphPad Prism software version 8.04 for Windows (GraphPad Software, San Diego, California USA) and GeneX 7.0 (GenEx™, Sweden). A value of p<0.05 was considered significant.

**Results**

**Preparation and characterization of nanoparticles**

The CSNP and gCSNP were fabricated by ion gelation method using TPP as the cross-linker. The physicochemical characteristics were estimated initially with the zeta sizer to establish the protocol for the size distribution of the nanoparticles. Table 2 summarizes the zeta sizer profile of the nanoparticles prepared by the ion gelation protocol. The size of CSNP were 155.1 ± 5.7 nm in diameter while the size of gCSNP were 181.1± 6.9 nm in diameter. The polydispersity index of both the NPs were between 0.35-0.4± 0.03. The NPs were later subjected to FTIR and XRD detection protocols to ascertain the conjugation and
the structure of the NP (Fig.1). Since the FTIR spectra between 4000–2500 cm−1 and 1000–400 cm−1 for all the samples were identical, these regions were not plotted. In the FTIR, the spectra of gCSNP was compared with those of CSNP, chitosan (CS) and GA. The FTIR spectra of the CS and its CSNPs revealed a new trough peak indicating the appearance of PO stretching at 1256 cm−1. The FTIR of CS was also compared with gCSNP. The characteristic transmittance trough of CS appeared at 1640, 1585, 1374 and 1150–1040 cm−1. In addition, significant changes in the troughs of amide III group around 1374 cm−1 could be observed. The gCSNPs displayed a decrease in the peak at 1320 and 1380 cm−1 cm−1.

Moreover, the intensity of (NH2) trough band at 1628 cm−1 found in CS decreased dramatically and a new band at 1550 cm-1 appeared denoting the cross-linking with TPP during the nanoparticle formation. The FTIR of CS was also compared with gCSNP. The characteristic transmittance trough of CS appeared at 1640, 1585, 1374 and 1150–1040 cm−1. In addition, significant changes in the troughs of amide III group around 1374 cm−1 could be observed. The gCSNP displayed a decrease in the peak at 1320 and 1380cm-1 attributed to the NH bending observed in the glucosamine units and at 1420/cm-1 (the symmetric NH3+ bending region) when compared with CSNPs. In addition, in gCSNP as compared to the CSNP, some changes in the spectra were observed at 1730 and 1640 cm−1 representing C = O stretching in esters and C = O stretch of chitosan amide.). The XRD spectrum of CS was compared with gCSNP (Figure 1,B). We observed a shift towards the right side in the case of gCSNP signifying an increase in the amorphous nature of the nanoparticle as compared to the CS.

**In vitro cytotoxicity assay of NP in HeLa 229 cells**

The doses for CSNP and gCSNP were chosen from the linear part of the cytotoxicity dose response curve (Fig. 2) accommodating the 50% viability (IC50) of the HeLa 229 cells after a 24 hour incubation. The IC50 of CSNP and gCSNP was recorded to be 4 μg/ml (Figure 2A) and 13.16 μg/ml (Figure 2B) respectively from the non-linear regression of the cytotoxicity curve. Hence, the effect of three test doses of CSNP and gCSNP on NLRP3 inflammasome-stimulated HeLa 229 cells was assessed (Fig.3 and Fig. 4). Fig. 3 represents the expression of (A)NLRP3, (B) PYCARD (for ASC protein), (C)Caspase 1 and (D) P2RX7 genes in the presence of CSNP/gCSNP, relative to control. LPS and ATP was taken as control since significant (p< 0.001) increase in ASC gene expression was observed in the presence of both, however neither LPS nor ATP alone produced any additional stimulation of NLRP3 and Caspase1 gene expression (Supplementary Fig. S1).

The relative mRNA expression of NLRP3 (Figure 3A) and PYCARD (Figure 3B) genes was observed to be significantly (p<0.0001) downregulated in HeLa 229 cells for all the three treatment doses (0.6 μg/ml, 6 μg/ml and 12 μg/ml) with CSNP as well as for the two treatment doses of 0.6 μg/ml and 6 μg/ml with gCSNP. However, a significant upregulation (p<0.0001) was noted in the relative mRNA expression of both NLRP3 as well as PYCARD genes when treated with 12 μg/ml of gCSNP. We observed that downregulation for NLRP3 at 0.6 μg/ml of gCSNP (~25 fold) was thrice of that observed with CSNP (~8 fold). However, downregulation for NLRP3 at 6 μg/ml was observed to be ~ 20-fold with both CSNP and gCSNP. In contrast at 12 μg/ml, although CSNP downregulated the expression of NLRP3 by ~ 20 fold, gCSNP upregulated its expression by ~ 12-fold. In case of PYCARD, its downregulation at 0.6 μg/ml with CSNP (~15 fold) was 3 times more compared to that of gCSNP (~5 fold). Similarly, downregulation for
PYCARD at 6 µg/ml was observed to be 4 times more with CSNP (~17-fold) when compared to gCSNP (~4 fold). In contrast at 12 µg/ml, although CSNP further downregulated the expression of PYCARD by ~20 fold, gCSNP upregulated its expression by ~5-fold. The Caspase 1 gene (Fig.3C) showed nominal variation in its relative mRNA expression. At a dose of 0.6 µg/ml, significant downregulation was observed only with gCSNP (p<0.05, ~2.6-fold). Significant downregulation was observed with CSNP at 6 µg/ml (p<0.001, ~2.6-fold) and 12 µg/ml (p<0.05, ~2.5-fold), although a significant upregulation was noted when treated with gCSNP for the two doses of 6 µg/ml (p<0.001, ~1.6-fold) and 12 µg/ml (p<0.0001, ~20-fold). Similar results were noted in case of the relative mRNA expression of P2RX7 gene (Fig. 3D) in the stimulated HeLa 229 cells with significant downregulation observed when treated with 6 µg/ml of CSNP (p<0.01, ~2-fold) and only 0.6 µg/ml of gCSNP (p<0.001, ~10-fold). However, for the highest concentration (12 µg/ml) of gCSNP, there was significant (p<0.001, ~25-fold) upregulation observed in the relative mRNA expression of P2RX7 gene.

Significant upregulation was observed in the relative mRNA expression of IL1β gene (Fig. 4A) for 6 µg/ml (p<0.0001, ~2-fold) and 12 µg/ml (p<0.0001, ~12-fold) of gCSNP in the stimulated HeLa 229 cells. Interestingly, IL1β protein secretion from stimulated HeLa 229 cells (Fig.4B) was observed to be significantly reduced in the presence of CSNP at 12 µg/ml (p<0.0001) along with 6 µg/ml and 0.6 µg/ml (p<0.01 respectively).

However, we observed that the conjugation of gallic acid reversed the immunosuppressor mimicking action of CSNP, as all three gCSNP doses significantly (p<0.0001) increased IL1β protein secretion in the extracellular solution of treated HeLa 229 cells.

**Discussion**

Inflammasomes are the multi-protein platform in the innate immune system that induce procaspase-1 activation and inflammatory cytokines maturation such as IL1β. Chitosan based nanoparticles are good immune enhancers by dint of being able to reverse cytokine changes in immunosuppression preclinical models (Mudgal et al. 2019). To explore the efficacy of the nanoparticles as immunomodulators in the HeLa 229 cell lines, we fabricated CSNP and gCSNP. The fabrication of the chitosan nanoparticles and the conjugation of gallic were analyzed with the FTIR. The FT-IR spectra of the CS and its CSNPs revealed a new trough peak indicating the appearance of PO stretching at 1256/cm. The characteristic transmittance trough of CS appeared at 1640, 1585, 1374 and 1150–1040 cm⁻¹. This corresponds to amide I, amide II, amide III groups, and glycosidic linkage (C—O—C), respectively (Pawlak and Mucha 2003). Moreover, the intensity of (NH₂) trough band at 1628/cm found in CS decreased dramatically and a new band at 1550/cm appeared. This confirmed the cross-linking of the TPP with chitosan to form the nanoparticles. The FTIR of CS was also compared with gCSNP. The characteristic transmittance trough of CS appeared at 1640, 1585, 1374 and 1150–1040 cm⁻¹. In addition, significant changes in the troughs of amide III group around 1374 cm⁻¹ could be observed (Wei and Gao 2016). The amide II trough bands around 1585 cm⁻¹ arose from the N—H bending vibrations coupled to C—N stretching vibrations. Amide III bands arose from the C—N stretching vibration. This might be due to the conjugation of GA to the amino group in CS in gCSNP (Wei and Gao 2016). The gCSNP displayed a decrease in the peak at 1320 and
1380/cm attributed to the NH bending observed in the glucosamine units and at 1420/cm (the symmetric NH$_3^+$ bending region) when compared with CSNPs. In addition, in gCSNP as compared to the CSNP, some changes in the spectra were observed at 1730 and 1640 cm$^{-1}$ representing C = O stretching in esters and C = O stretch of chitosan amide (Wei and Gao 2016). The conjugation of GA with CS was also confirmed by XRD which revealed an increase of amorphous characteristic due to a reduction of the inter and intra hydrogen bonds. This is in agreement with the results by other groups (Pasanphan et al. 2008; Pasanphan and Chirachanchai 2008). The size of the engineered nanoparticles is another factor which determines the bio-nano interaction (Nel et al. 2006). The size effect of ENMs on NLRP3 inflammasome activation has been examined with the nanoparticles in the lower range showing pronounced effects on IL-1b production. by several studies, though contradictory results were obtained (Sun et al. 2013). The effect of the size on the NLRP3 inflammasome regulation was studied with CSNP and gCSNP. The size of CSNP were found to be 155 nm while the encapsulation of GA increased the size by 26 nm to 181.1 nm. The encapsulation efficiency of GA was found to be 90.2% based on the already reported earlier (Lamarra et al. 2016).

Activation of NLRP3 inflammasome involves coordinated processes between stimuli and cells. Based on in vitro studies, it has been demonstrated that two signals are generally required to activate the NLRP3 inflammasome (Tschopp and Schroder 2010). For signal 1, pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharides (LPS) molecule is recognized by Toll-like receptor 4 (TLR4) residing on cell membrane, releasing ROS, which further leads to NF-κB and increases the production of pro-IL-1β and NLRP3 proteins (Bryant and Fitzgerald 2009). For signal 2, upon activation and assembly of NLRP3 inflammasome complex by various stimuli including ATP or ENMs, the pro-IL-1β is further processed to mature IL-1β. The nanoparticles were fabricated based on the hypothesis that CSNP due to improved surface area would act as antioxidant curbing the NLRP3 inflammasome and its activity would be further augmented by gallic acid conjugation. Three different models have been proposed for the NLRP3 inflammasome activation. In the present paper, we have tried to explore the K$^+$ efflux model. Extracellular ATP is a NLRP3 agonist that is released at sites of cellular injury or necrosis. ATP-mediated inflammasome activation depends on activation of the P2X7 ATP-gated ion channel, which triggers rapid K$^+$ efflux from the cell (Tschopp and Schroder 2010).

In the context of the present study, the CSNP induced downregulation of NLRP3 inflammasome complex genes in cervical cancer cells, might prove beneficial in ameliorating the adverse effects of inflammasome gene expression thus avoiding the ensuing adjacent normal tissue damage. Thus, this immunosuppressor mimicking activity of CSNP can potentially inhibit the infiltration of myeloid and myeloid derived cells, thereby preventing the development of inflammatory microenvironment around cancer cells to attenuate tumour progression$^7$.

Through our study, we infer that the conjugation of gallic acid reversed the immunosuppressor mimicking action of CSNP, indicated by the release of proinflammatory cytokine IL1β from HeLa 229 cells. It is known that gallic acid and CSNP work synergistically as is observed in our study where in contrast to
CSNP alone, gCSNP upregulated the expression of genes coding for NLRP3 inflammasome pathway as part of the priming signal (Hamarsheh and Zeiser 2020; Mudgal et al. 2019; Zheng et al. 2018). Hence, we infer that CSNP alone at 155 nm size, downregulated the expression of genes coding for NLRP3 inflammasome complex even at higher doses. The present study demonstrated how a bifunctional role of CSNP can be elicited with the mere conjugation of gallic acid, by reversing its role in HeLa 229 cells. This allowed an unopposed priming signal for the inflammasome complex proteins. This effect on the priming signal by gCSNP could be due to the physicochemical property of the nanoparticle and its interaction with the biological system that is occurring at the nano-bio interface.

Furthermore, with respect of the activation signal, our study helps to infer that unlike gCSNP, CSNP was also effective in controlling the formation of NLRP3 inflammasome complex probably by inhibiting the P2RX7 gene even in the presence of external ATP. Upregulation of P2RX7 receptor protein through K⁺ efflux has been shown to influence the NLRP3 inflammasome complex formation that results in increased IL-1β release (Hamarsheh and Zeiser 2020; Kantono and Guo 2017; Karki and Kanneganti 2019). The significant increase in the IL1β secretion from HeLa 229 cells when treated with gCSNP indicate that conjugating gallic acid led to the reversal of drug action. To the best of our knowledge, we demonstrated for the first time that conjugation of gallic acid reverses the immunosuppressor mimicking property of CSNP in NLRP3 inflammasome stimulated HeLa 229 cell line model. We can speculate within reason that the conjugation of gallic acid with CSNP could potentially activate the NLRP3 inflammasome. It is known that nanoparticles, activate the NLRP3 inflammasome through interaction with adenosine receptors by inducing ATP release (Jo et al. 2016). In the presence of higher doses of gCSNP, the increased IL1β release from cervical cancer cells accompanied with the upregulation of P2RX7 gene implicated the unopposed activation of NLRP3 inflammasome complex.

**Conclusions**

The present study demonstrated that the role reversal of CSNP can be achieved when conjugated with gallic acid at higher doses. Interestingly, given its wide range of safe limits of cytotoxicity, as observed in our study, alternative administration time can be tested to come to a conclusion in case of HeLa 229 cells. Additionally, on a larger perspective, it is an interesting finding to note that gallic acid conjugated nanoparticles have the potential to act as an immunomodulator as is indicated by the upregulation of IL1β. However, the limitation of this study involves the lack of experimental data demonstrating the interaction of NLRP3, ASC, Caspase 1 and P2RX7 proteins subsequent to the effect of the NPs on HeLa 229 cell line model. Furthermore, the metabolic consequences of tumor microenvironment influencing the cancer hallmark of immune evasion in the context of the present study, would unravel important information regarding the role of the NPs.

Hence, future research coupling the protein expression along with the gene expression of the genes coding for the NLRP3 inflammasome complex in treated HeLa 229 cell line model can reveal the immunomodulatory mechanism of CSNP which may have its translational significance as potential treatment strategies for cancer.
Abbreviations
CSNP, chitosan nanoparticle; gCSNP, gallic acid conjugated chitosan nanoparticle; GA, gallic acid; LPS, lipopolysaccharide; ATP, adenosine triphosphate; ENM: Engineered Nano Materials

Declarations

Acknowledgments
We thank Linda Bobby Tholath and Jesna Suresh (MIT, MAHE) for their assistance with the cytotoxicity assays. The authors would also like to thank MIT, MAHE for the infrastructure help and MAHE for funding the research work.

Authors’ contributions
RR designed the experimental protocols, performed synthesis and characterization of the nanoparticles and performed cell culture analytical experiments and the results analysis of the samples. RC and UB designed the experimental protocols, performed the experiments and did the results analysis of the cell culture experiments. GP performed the experiments of the cell culture. SRS contributed in maintaining the cell culture. RR, RC, UB and SRS contributed to writing the manuscript.

All authors reviewed the final draft of the manuscript. All authors read and approved the final manuscript.

Funding
The work was carried out under the seed grant scheme (Grant No. 00000387) awarded by MAHE, Manipal to conduct the experiments.

Availability of data and materials
The data will be available if needed.

Ethics approval and consent to participate
Not Applicable.

Consent for publication
All authors agree with the publication of this manuscript in this journal.

Competing interests
The authors declare that there is no conflict of interest

References
Ainsworth EA, Gillespie KM. Estimation of total phenolic content and other oxidation substrates in plant tissues using Folin-Ciocalteu reagent. Nat. Protoc. England; 2007;2(4):875–7.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob. Heal. [Internet]. Elsevier; 2020 Feb 1;8(2):e191–203. Available from: https://doi.org/10.1016/S2214-109X(19)30482-6

Bryant C, Fitzgerald KA. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol. England; 2009 Sep;19(9):455–64.

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. United States; 2009 Apr;55(4):611–22.

Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. United States; 1997 Oct;14(10):1431–6.

Hamarsheh S, Zeiser R. NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword. Front. Immunol. 2020;11:1444.

Jo E-K, Kim JK, Shin D-M, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell. Mol. Immunol. China; 2016 Mar;13(2):148–59.

Kantono M, Guo B. Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development. Front. Immunol. 2017;8:1132.

Karki R, Kanneganti T-D. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat. Rev. Cancer. 2019 Apr;19(4):197–214.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 – latest trends. J. Exp. Clin. Cancer Res. [Internet]. 2019;38(1):268. Available from: https://doi.org/10.1186/s13046-019-1266-0

Lamarra J, Giannuzzi L, Rivero S, Pinotti A. Assembly of chitosan support matrix with gallic acid-functionalized nanoparticles. Mater. Sci. Eng. C [Internet]. 2017;79:848–59. Available from: http://www.sciencedirect.com/science/article/pii/S0928493116327576

Lamarra J, Rivero S, Pinotti A. Design of chitosan-based nanoparticles functionalized with gallic acid. Mater. Sci. Eng. C. 2016;67:717–26.

Mishra GA, Pimple SA, Shastri SS. Prevention of Cervix Cancer in India. Oncology. Switzerland; 2016;91 Suppl 1:1–7.
Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol. Cancer [Internet]. 2018;17(1):158. Available from: https://doi.org/10.1186/s12943-018-0900-3

Mudgal J, Mudgal PP, Kinra M, Raval R. Immunomodulatory role of chitosan-based nanoparticles and oligosaccharides in cyclophosphamide-treated mice. Scand. J. Immunol. [Internet]. John Wiley & Sons, Ltd; 2019 Apr 1;89(4):e12749. Available from: https://doi.org/10.1111/sji.12749

Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science. United States; 2006 Feb;311(5761):622–7.

Park W, Heo YJ, Han DK. New opportunities for nanoparticles in cancer immunotherapy. Biomater. Res. BioMed Central Ltd; 2018.

Pasanphan W, Buettner GR, Chirachanchai S. Chitosan conjugated with deoxycholic acid and gallic acid: A novel biopolymer-based additive antioxidant for polyethylene. J. Appl. Polym. Sci. John Wiley & Sons, Ltd; 2008 Jul;109(1):38–46.

Pasanphan W, Chirachanchai S. Conjugation of gallic acid onto chitosan: An approach for green and water-based antioxidant. Carbohydr. Polym. 2008;72(1):169–77.

Pawlak A, Mucha M. Thermogravimetric and FTIR studies of chitosan blends. Thermochim. Acta. 2003;396(1):153–66.

Pontillo A, Bricher P, Leal VNC, Lima S, Souza PRE, Crovella S. Role of inflammasome genetics in susceptibility to HPV infection and cervical cancer development. J. Med. Virol. [Internet]. John Wiley & Sons, Ltd; 2016 Sep 1;88(9):1646–51. Available from: https://doi.org/10.1002/jmv.24514

Sun B, Wang X, Ji Z, Li R, Xia T. NLRP3 inflammasome activation induced by engineered nanomaterials. Small. 2013 May;9(9–10):1595–607.

Sun W. Recent advances in cancer immunotherapy. J. Hematol. Oncol. [Internet]. 2017;10(1):96. Available from: https://doi.org/10.1186/s13045-017-0460-9

Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. England; 2010. p. 210–5.

Wei Z, Gao Y. Evaluation of structural and functional properties of chitosan-chlorogenic acid complexes. Int. J. Biol. Macromol. Netherlands; 2016 May;86:376–82.

Zheng M, Zhang C, Zhou Y, Lu Z, Zhao H, Bie X, et al. Preparation of Gallic Acid-Grafted Chitosan Using Recombinant Bacterial Laccase and Its Application in Chilled Meat Preservation. Front. Microbiol. 2018;9:1729.
### Tables

**Table 1.** TaqMan catalogue number for genes used in the qPCR experiments.

| Gene name                                               | Catalogue number (TaqMan code) |
|---------------------------------------------------------|---------------------------------|
| Hypoxanthine phosphoribosyltransferase 1 (HPRT1)       | Hs02800695_m1                   |
| Actin beta (ACTB)                                       | Hs01060665_g1                   |
| glyceraldehyde-3-phosphate dehydrogenase (GAPDH)       | Hs02786624_g1                   |
| NLR family pyrin domain containing 3 (NLRP3)            | Hs00918082_m1                   |
| PYD and CARD domain containing (PYCARD)                | Hs01547324_gH                   |
| Caspase 1 (CASP1)                                       | Hs00354836_m1                   |
| Purinergic receptor P2X 7 (P2RX7)                       | Hs00175721_m1                   |
| Interleukin 1 beta (IL-1β)                             | Hs01555410_m1                   |

**Table 2.** Size distribution of the NPs as determined by the Zeta sizer. The percentage encapsulation of gCSNP has also been computed.

| CH% | Ch:TPP | GA (mg/gCH) | ZP (mV) | Diameter | PDI | PEE  |
|-----|--------|-------------|--------|----------|-----|------|
| 0.25| 1:5    |             | 58.1   | 155.1    | 0.4 |      |
| 0.25| 1:5    | 50          | 78.1   | 181.1    | 0.35| 90.2 |

### Figures
Figure 1
FTIR spectrum data and XRD pattern data for nanoparticles. [A] FTIR spectrum of CS, CSNP, gCSNP and GA. [B] XRD pattern for CS(red) and gCSNP (blue).

Figure 2
Cytotoxicity (24 hours) of CSNP and gCSNP in HeLa 229 cells. The log doses (ranging between 5 ng/ml – 3 mg/ml) of CSNP and gCSNP preparations were assessed for cytotoxicity in HeLa 229 cells for 24 hours. The percent viability in the presence of the nanoparticle preparations compared to drug free control was evaluated using MTT proliferation assay kit. n ≥ 3.
Relative expression of genes coding for NLRP3 inflammasome in HeLa 229 cells post stimulation with LPS and ATP. The effect of three test doses (0.6 µg/ml, 6 µg/ml and 12 µg/ml) of CSNP and gCSNP on the expression of genes coding for NLRP3 inflammasome complex have been represented. The expression of (A) NLRP3, (B) ASC (PYCARD), (C) Caspase 1 and (D) P2RX7 gene is represented relative to their expression in HeLa 229 cells after stimulation with LPS (0 hr) and ATP (3.5 hrs). The test nanoparticles were administered at 0 hr and harvested at 4.5 hrs of the experiments. * = p<0.05, ** = p<0.01 *** = p<0.001 and **** = p<0.0001. n > 3. The relative mRNA expression of NLRP3 (Figure 3A) and PYCARD (Figure 3B) genes was observed to be significantly (p<0.0001) downregulated in HeLa 229 cells for all the three treatment doses with CSNP as well as for the two treatment doses of 0.6 µg/ml and 6 µg/ml with gCSNP. However, a significant upregulation (p<0.0001) was noted in the relative mRNA expression of both NLRP3 as well as PYCARD genes when treated with 12 µg/ml of gCSNP. However at 0.6 µg/ml of gCSNP, the downregulation observed for NLRP3 (~25 fold) was thrice of that observed
with CSNP (~8 fold). But, downregulation for NLRP3 at 6 µg/ml was observed to be ~ 20-fold with both CSNP and gCSNP. In contrast at 12 µg/ml, although CSNP downregulated the expression of NLRP3 by ~20 fold, gCSNP upregulated its expression by ~ 12-fold. In case of PYCARD, its downregulation at 0.6 µg/ml with CSNP (~15 fold) was 3 times more compared to that of gCSNP (~5 fold).

Figure 4

Relative expression of IL-1β gene and protein expression in HeLa 229 cells post stimulation with LPS and ATP. The effect of three test doses (0.6 µg/ml, 6 µg/ml and 12µg/ml) of CSNP and gCSNP, administered at the beginning and harvested at 4.5 hrs on (A) The expression of IL1β gene, relative to their expression in HeLa 229 cells stimulated with LPS (0 hr) and ATP (3.5 hrs). (B) The expression of IL1β in supernatant/spent media of stimulated HeLa 229 cells. * = p<0.05, ** = p<0.01 *** = p<0.001 and **** = p<0.0001. n ≥ 3. Significant upregulation was observed in the relative mRNA expression of IL1β gene (Figure 4A) for 6 µg/ml (p<0.0001, ~2-fold) and 12 µg/ml (p<0.0001, ~12 fold) of gCSNP in the stimulated HeLa 229 cells. Interestingly, IL1β protein secretion from stimulated HeLa 229 cells (Figure 4B) was observed to be significantly reduced in the presence of CSNP at 12 µg/ml (p<0.0001) along with 6 µg/ml and 0.6 µg/ml (p<0.01 respectively). However, we observed that the conjugation of gallic acid reversed the immunosuppressor mimicking action of CSNP, as all three gCSNP doses significantly (p<0.0001) increased IL1β protein secretion in the extracellular solution of treated HeLa 229 cells.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- graphicalabstractfigure.docx
- supplementary.docx